CN Patent

CN103933570A — S1p受体调节剂的给药方案

Assigned to Novartis AG · Expires 2014-07-23 · 12y expired

What this patent protects

本发明涉及S1P受体调节剂的给药方案。更具体而言，本发明涉及在罹患炎性或自身免疫性疾病或障碍(例如多发性硬化(MS))的患者的治疗过程中S1P受体调节剂或激动剂的给药方案。

USPTO Abstract

本发明涉及S1P受体调节剂的给药方案。更具体而言，本发明涉及在罹患炎性或自身免疫性疾病或障碍(例如多发性硬化(MS))的患者的治疗过程中S1P受体调节剂或激动剂的给药方案。

Drugs covered by this patent

fingolimod-hydrochloride (FINGOLIMOD HYDROCHLORIDE)

Patent Metadata

Patent number: CN103933570A
Jurisdiction: CN
Classification: —
Expires: 2014-07-23
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.